Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters
FDA's recognition accelerates the path for advanced AI-enabled risk assessment in breast cancer screening. Improved prediction can enhance early intervention and personalisation, potentially reducing morbidity and mortality.
Source
Health Imaging
Related News
•Radiology Business
NYC Health + Hospitals CEO Considers AI to Replace Radiologists
NYC Health + Hospitals CEO suggests AI could partially replace radiologists, pending regulatory approval.
•Radiology Business
UCLA Appoints Inaugural Associate Dean for Health AI Strategy
UCLA has appointed Katherine P. Andriole as its first associate dean for Health AI Strategy and Innovation, with an initial focus on radiology.
•AuntMinnie
AI Models Reveal Racial Disparities in Breast Cancer Patterns
Machine learning models reveal significant racial disparities and key predictors in breast cancer incidence across diverse groups.